Telix Pharmaceuticals (NASDAQ:TLX) Receives "Outperform" Rating from Wedbush

Key Points

• Wedbush reiterated an “Outperform” rating on Telix Pharmaceuticals and set a $22 price target, implying approximately 78.9% upside from the prior close.
• Analyst sentiment remains positive overall, with a consensus rating of “Moderate Buy” and an average price target of $20.40, despite ratings ranging from Strong Buy to Sell.
• Telix reported quarterly EPS of $0.05, exceeding the $0.04 consensus estimate, while shares traded at $12.30 and institutional investors generally increased their positions.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report)'s stock had its "outperform" rating reiterated by equities research analysts at Wedbush in a note issued to investors on Thursday,Benzinga reports. They presently have a $22.00 target price on the stock. Wedbush's price objective would suggest a potential upside of 78.86% from the company's previous close.

Other analysts also recently issued reports about the stock. Weiss Ratings restated a "sell (d)" rating on shares of Telix Pharmaceuticals in a report on Friday, July 17th. HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Tuesday, July 7th. Citigroup restated a "buy" rating on shares of Telix Pharmaceuticals in a report on Thursday. Finally, Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $20.40.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ TLX traded up $0.18 during midday trading on Thursday, reaching $12.30. 180,019 shares of the stock were exchanged, compared to its average volume of 195,443. Telix Pharmaceuticals has a 12 month low of $6.28 and a 12 month high of $12.60. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The business has a 50-day simple moving average of $10.87 and a two-hundred day simple moving average of $9.60.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last issued its quarterly earnings data on Thursday, August 20th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.04 by $0.01. The business had revenue of $238.68 million for the quarter, compared to analyst estimates of $479.63 million. On average, analysts anticipate that Telix Pharmaceuticals will post 0.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Lazard Asset Management LLC lifted its stake in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company's stock valued at $2,775,000 after acquiring an additional 39,400 shares during the last quarter. Portland Investment Counsel Inc. increased its stake in shares of Telix Pharmaceuticals by 108.0% during the 4th quarter. Portland Investment Counsel Inc. now owns 266,200 shares of the company's stock worth $2,063,000 after purchasing an additional 138,200 shares during the last quarter. Millennium Management LLC bought a new stake in shares of Telix Pharmaceuticals in the 3rd quarter valued at about $1,883,000. Private Advisor Group LLC raised its holdings in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company's stock valued at $1,669,000 after purchasing an additional 128,070 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in Telix Pharmaceuticals in the 2nd quarter valued at about $1,731,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source